Cytarabine is an approved anti-cancer drug used mainly in combination with other agents for the treatment of a form of cancer called acute myeloblastic leukaemia. It is has also been reported to beneficial in the treatment of progressive multifocal leukoencephalopathy (PML) in some case reports, although in other reports it has not been effective.

The drug can be given by intravenous, subcutaneous or intrathecal injection. It strongly suppresses the bone marrow and can cause a range of blood disorders, as well as nausea, vomiting, fever, anorexia and mouth ulcers.

It is also known as cytosine arabinoside, or ara-C. It is available as a generic (non-brandname) drug, and is also manufactured by Pfizer under the brandname Alexan and by Pharmacia & Upjohn under the brandname Cytosar.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.